Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

BACKGROUND: Large type 3 and type 4 gastric cancers have extremely poor prognoses. To address this, neoadjuvant chemotherapy may be a promising approach. The phase III JCOG0501 study, conducted to confirm the superiority of neoadjuvant S-1 plus cisplatin followed by D2 gastrectomy over upfront surge...

Descripción completa

Detalles Bibliográficos
Autores principales: Endo, Shunji, Terazawa, Tetsuji, Goto, Masahiro, Tanaka, Ryo, Kato, Takeshi, Fujitani, Kazumasa, Kawakami, Hisato, Sakai, Daisuke, Kurokawa, Yukinori, Tsujinaka, Toshimasa, Shimokawa, Toshio, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308238/
https://www.ncbi.nlm.nih.gov/pubmed/35870893
http://dx.doi.org/10.1186/s12885-022-09890-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308238/
https://www.ncbi.nlm.nih.gov/pubmed/35870893
http://dx.doi.org/10.1186/s12885-022-09890-w

Ejemplares similares